ONTOLOGY REPORT - ANNOTATIONS
| Term: | (S)-colchicine |
|
| Accession: | CHEBI:27882
|
browse the term
|
| Definition: | A colchicine that has formula C22H25NO6. |
| Synonyms: | exact_synonym: | N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide |
| | related_synonym: | (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7alphaH-colchicine; C22H25NO6; COc1cc2CC[C@H](NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC; Colchicin; Colchicine; InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1; InChIKey=IAKHMKGGTNLKSZ-INIZCTEOSA-N; colchicina; colchicinum |
| | alt_id: | CHEBI:3811 |
| | xref_casrn: | 64-86-8 |
| | xref: | Beilstein:2228813 "Beilstein Registry Number"; ChEMBL:114440 "ChEMBL COMPOUND"; ChemIDplus:64-86-8 "CAS Registry Number"; DrugBank:DB01394 "DrugBank"; KEGG COMPOUND:64-86-8 "CAS Registry Number"; KEGG COMPOUND:C07592 "KEGG COMPOUND"; KEGG DRUG:D00570 "KEGG DRUG" |
| | xref_mesh: | MESH:D003078 |
| | xref: | NIST Chemistry WebBook:64-86-8 "CAS Registry Number"; Wikipedia:Colchicine "Wikipedia" |
| | cyclic_relationship: | is_enantiomer_of CHEBI:51074 |
|
|
(S)-colchicine
|
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
affects localization |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcb11 |
ATP-binding cassette, subfamily B (MDR/TAP), member 11 |
|
affects localization |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects transport |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases export |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
decreases response to substance |
ISO |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
affects localization |
EXP |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcc4 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 4 |
|
multiple interactions |
ISO |
15 |
103,384,848 |
103,611,238 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases activity |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases expression |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
multiple interactions |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases activity |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases activity |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases activity |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ace |
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 |
|
decreases activity |
EXP |
10 |
95,361,338 |
95,381,455 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
decreases activity |
ISO |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Ahr |
aryl hydrocarbon receptor |
|
decreases activity |
EXP |
6 |
54,205,104 |
54,240,268 |
RGD:6480464 |
CTD |
| G |
Aif1 |
allograft inflammatory factor 1 |
|
decreases expression |
EXP |
20 |
3,714,428 |
3,716,327 |
RGD:6480464 |
CTD |
| G |
Ak1 |
adenylate kinase 1 |
|
decreases expression |
EXP |
2 |
19,821,482 |
19,822,544 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
affects expression |
ISO |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Alb |
albumin |
|
multiple interactions |
EXP |
14 |
19,126,935 |
19,142,214 |
RGD:6480464 |
CTD |
| G |
Apln |
apelin |
|
decreases expression |
EXP |
X |
134,387,285 |
134,396,762 |
RGD:6480464 |
CTD |
| G |
Aurkb |
aurora kinase B |
|
increases expression |
ISO |
10 |
55,798,710 |
55,804,367 |
RGD:6480464 |
CTD |
| G |
Avp |
arginine vasopressin |
|
decreases transport |
EXP |
3 |
118,205,007 |
118,206,985 |
RGD:6480464 |
CTD |
| G |
Bax |
Bcl2-associated X protein |
|
increases expression |
ISO |
1 |
95,933,023 |
95,938,176 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
multiple interactions |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
decreases expression |
ISO |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bcl2l1 |
Bcl2-like 1 |
|
multiple interactions |
EXP |
3 |
143,129,087 |
143,180,199 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
decreases transport |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
C3 |
complement component 3 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Capn1 |
calpain 1, (mu/I) large subunit |
|
decreases expression |
EXP |
1 |
208,620,286 |
208,645,007 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases cleavage |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
multiple interactions |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases activity |
ISO |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Casp8 |
caspase 8 |
|
increases expression |
EXP |
9 |
57,389,353 |
57,437,803 |
RGD:6480464 |
CTD |
| G |
Casp9 |
caspase 9, apoptosis-related cysteine peptidase |
|
increases activity |
ISO |
5 |
160,704,234 |
160,721,796 |
RGD:6480464 |
CTD |
| G |
Cat |
catalase |
|
increases expression |
EXP |
3 |
88,654,077 |
88,686,212 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccl2 |
chemokine (C-C motif) ligand 2 |
|
increases expression |
EXP |
10 |
70,256,263 |
70,258,061 |
RGD:6480464 |
CTD |
| G |
Ccnb1 |
cyclin B1 |
|
increases expression |
ISO |
2 |
31,574,600 |
31,581,784 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
increases expression |
EXP |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Cd14 |
CD14 molecule |
|
increases expression |
EXP |
18 |
29,374,593 |
29,376,190 |
RGD:6480464 |
CTD |
| G |
Cd44 |
Cd44 molecule |
|
increases expression |
EXP |
3 |
88,022,962 |
88,110,352 |
RGD:6480464 |
CTD |
| G |
Cd59 |
CD59 molecule, complement regulatory protein |
|
increases mutagenesis |
ISO |
3 |
89,243,600 |
89,245,129 |
RGD:6480464 |
CTD |
| G |
Cdh1 |
cadherin 1 |
|
affects activity |
ISO |
19 |
36,442,693 |
36,512,091 |
RGD:6480464 |
CTD |
| G |
Cdk2 |
cyclin dependent kinase 2 |
|
increases expression |
EXP |
7 |
2,000,196 |
2,007,682 |
RGD:6480464 |
CTD |
| G |
Cdk5 |
cyclin-dependent kinase 5 |
|
increases expression |
EXP |
4 |
6,119,704 |
6,124,186 |
RGD:6480464 |
CTD |
| G |
Cdk5 |
cyclin-dependent kinase 5 |
|
multiple interactions |
EXP |
4 |
6,119,704 |
6,124,186 |
RGD:6480464 |
CTD |
| G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
|
increases expression |
EXP |
20 |
7,376,325 |
7,386,778 |
RGD:6480464 |
CTD |
| G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
|
decreases expression |
EXP |
15 |
22,617,409 |
22,624,922 |
RGD:6480464 |
CTD |
| G |
Celf2 |
CUGBP, Elav-like family member 2 |
|
multiple interactions |
ISO |
17 |
82,708,354 |
83,025,139 |
RGD:6480464 |
CTD |
| G |
Celf2 |
CUGBP, Elav-like family member 2 |
|
increases expression |
ISO |
17 |
82,708,354 |
83,025,139 |
RGD:6480464 |
CTD |
| G |
Cp |
ceruloplasmin (ferroxidase) |
|
increases expression |
EXP |
2 |
105,086,278 |
105,135,367 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
decreases expression |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Crh |
corticotropin releasing hormone |
|
increases expression |
EXP |
2 |
104,764,023 |
104,765,887 |
RGD:6480464 |
CTD |
| G |
Csf2 |
colony stimulating factor 2 (granulocyte-macrophage) |
|
multiple interactions |
ISO |
10 |
39,665,850 |
39,667,831 |
RGD:6480464 |
CTD |
| G |
Cxcl1 |
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) |
|
increases expression |
EXP |
14 |
18,690,339 |
18,692,118 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
multiple interactions |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Drd3 |
dopamine receptor D3 |
|
decreases expression |
EXP |
11 |
58,446,901 |
58,520,589 |
RGD:6480464 |
CTD |
| G |
Ednrb |
endothelin receptor type B |
|
increases expression |
EXP |
15 |
87,893,141 |
87,898,700 |
RGD:6480464 |
CTD |
| G |
Eprs |
glutamyl-prolyl-tRNA synthetase |
|
increases expression |
EXP |
13 |
101,375,656 |
101,448,175 |
RGD:6480464 |
CTD |
| G |
Esm1 |
endothelial cell-specific molecule 1 |
|
decreases expression |
EXP |
2 |
44,626,010 |
44,634,748 |
RGD:6480464 |
CTD |
| G |
F2 |
coagulation factor II |
|
affects activity |
ISO |
3 |
76,005,318 |
76,018,603 |
RGD:6480464 |
CTD |
| G |
F3 |
coagulation factor III (thromboplastin, tissue factor) |
|
increases expression |
EXP |
2 |
218,371,050 |
218,382,645 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
increases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fas |
Fas (TNF receptor superfamily, member 6) |
|
decreases expression |
ISO |
1 |
238,259,443 |
238,274,745 |
RGD:6480464 |
CTD |
| G |
Fcgr2b |
Fc fragment of IgG, low affinity IIb, receptor (CD32) |
|
increases expression |
EXP |
13 |
86,809,011 |
86,823,599 |
RGD:6480464 |
CTD |
| G |
Fgf2 |
fibroblast growth factor 2 |
|
affects expression |
EXP |
2 |
123,893,314 |
123,947,136 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
increases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
|
increases expression |
EXP |
4 |
96,649,941 |
96,652,243 |
RGD:6480464 |
CTD |
| G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
|
increases expression |
EXP |
7 |
10,289,073 |
10,291,102 |
RGD:6480464 |
CTD |
| G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
|
increases expression |
EXP |
17 |
19,230,896 |
19,232,641 |
RGD:6480464 |
CTD |
| G |
Gas7 |
growth arrest specific 7 |
|
decreases expression |
EXP |
10 |
54,312,438 |
54,403,868 |
RGD:6480464 |
CTD |
| G |
Gja1 |
gap junction protein, alpha 1 |
|
multiple interactions |
EXP |
20 |
35,409,815 |
35,422,262 |
RGD:6480464 |
CTD |
| G |
Gpx1 |
glutathione peroxidase 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Gsk3b |
glycogen synthase kinase 3 beta |
|
decreases expression |
EXP |
11 |
64,284,731 |
64,428,698 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Icam1 |
intercellular adhesion molecule 1 |
|
increases expression |
EXP |
8 |
20,040,177 |
20,051,939 |
RGD:6480464 |
CTD |
| G |
Ikbkb |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
|
increases phosphorylation |
ISO |
16 |
73,804,730 |
73,858,510 |
RGD:6480464 |
CTD |
| G |
Ikbkb |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
|
multiple interactions |
ISO |
16 |
73,804,730 |
73,858,510 |
RGD:6480464 |
CTD |
| G |
Ikbkb |
inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta |
|
affects response to substance |
ISO |
16 |
73,804,730 |
73,858,510 |
RGD:6480464 |
CTD |
| G |
Il1b |
interleukin 1 beta |
|
increases expression |
EXP |
3 |
116,964,422 |
116,970,867 |
RGD:6480464 |
CTD |
| G |
Il2 |
interleukin 2 |
|
decreases expression |
ISO |
2 |
123,655,005 |
123,659,709 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
EXP |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Inha |
inhibin alpha |
|
decreases expression |
EXP |
9 |
74,781,223 |
74,784,124 |
RGD:6480464 |
CTD |
| G |
Ins1 |
insulin 1 |
|
multiple interactions |
EXP |
1 |
258,001,134 |
258,001,688 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases phosphorylation |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
increases activity |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
ISO |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Jun |
jun proto-oncogene |
|
multiple interactions |
EXP |
5 |
115,358,166 |
115,361,259 |
RGD:6480464 |
CTD |
| G |
Krt18 |
keratin 18 |
|
decreases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
increases phosphorylation |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk8 |
mitogen-activated protein kinase 8 |
|
multiple interactions |
ISO |
16 |
8,925,133 |
9,004,897 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
increases phosphorylation |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mapk9 |
mitogen-activated protein kinase 9 |
|
multiple interactions |
ISO |
10 |
35,353,486 |
35,384,319 |
RGD:6480464 |
CTD |
| G |
Mapt |
microtubule-associated protein tau |
|
decreases expression |
ISO |
10 |
93,411,098 |
93,508,762 |
RGD:6480464 |
CTD |
| G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
|
multiple interactions |
ISO |
1 |
196,629,366 |
196,866,937 |
RGD:6480464 |
CTD |
| G |
Mpo |
myeloperoxidase |
|
multiple interactions |
EXP |
10 |
76,085,872 |
76,097,012 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myc |
myelocytomatosis oncogene |
|
increases expression |
EXP |
7 |
98,953,142 |
98,958,060 |
RGD:6480464 |
CTD |
| G |
Myt1 |
myelin transcription factor 1 |
|
increases phosphorylation |
ISO |
3 |
170,954,769 |
170,985,583 |
RGD:6480464 |
CTD |
| G |
Nbn |
nibrin |
|
increases expression |
EXP |
5 |
30,541,610 |
30,576,168 |
RGD:6480464 |
CTD |
| G |
Ndufs4 |
NADH dehydrogenase (ubiquinone) Fe-S protein 4 |
|
affects response to substance |
ISO |
2 |
45,839,236 |
46,479,619 |
RGD:6480464 |
CTD |
| G |
Nfatc4 |
nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 4 |
|
decreases localization |
ISO |
15 |
33,969,774 |
33,978,848 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
increases phosphorylation |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nfkbia |
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
|
multiple interactions |
ISO |
6 |
75,729,302 |
75,732,475 |
RGD:6480464 |
CTD |
| G |
Nos1 |
nitric oxide synthase 1, neuronal |
|
increases expression |
EXP |
12 |
39,812,500 |
39,869,484 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
multiple interactions |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nptx1 |
neuronal pentraxin I |
|
increases expression |
EXP |
10 |
108,918,661 |
108,927,616 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases activity |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases degradation |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nts |
neurotensin |
|
increases expression |
EXP |
7 |
40,474,654 |
40,484,058 |
RGD:6480464 |
CTD |
| G |
Odc1 |
ornithine decarboxylase 1 |
|
multiple interactions |
ISO |
6 |
41,309,211 |
41,315,796 |
RGD:6480464 |
CTD |
| G |
Odc1 |
ornithine decarboxylase 1 |
|
increases expression |
EXP |
6 |
41,309,211 |
41,315,796 |
RGD:6480464 |
CTD |
| G |
Pawr |
PRKC, apoptosis, WT1, regulator |
|
increases expression |
EXP |
7 |
47,040,162 |
47,119,613 |
RGD:6480464 |
CTD |
| G |
Pawr |
PRKC, apoptosis, WT1, regulator |
|
multiple interactions |
EXP |
7 |
47,040,162 |
47,119,613 |
RGD:6480464 |
CTD |
| G |
Plagl1 |
pleiomorphic adenoma gene-like 1 |
|
increases expression |
EXP |
1 |
7,882,674 |
7,922,504 |
RGD:6480464 |
CTD |
| G |
Plat |
plasminogen activator, tissue |
|
increases expression |
EXP |
16 |
73,711,323 |
73,736,328 |
RGD:6480464 |
CTD |
| G |
Plaur |
plasminogen activator, urokinase receptor |
|
increases expression |
EXP |
1 |
79,708,646 |
79,712,881 |
RGD:6480464 |
CTD |
| G |
Pomc |
proopiomelanocortin |
|
increases secretion |
EXP |
6 |
26,931,969 |
26,937,789 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Potef |
POTE ankyrin domain family, member F |
|
multiple interactions |
EXP |
18 |
24,420,779 |
24,422,284 |
RGD:6480464 |
CTD |
| G |
Ppp1ca |
protein phosphatase 1, catalytic subunit, alpha isozyme |
|
increases expression |
ISO |
1 |
206,774,719 |
206,778,336 |
RGD:6480464 |
CTD |
| G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
|
increases expression |
EXP |
1 |
95,994,023 |
95,997,080 |
RGD:6480464 |
CTD |
| G |
Ptk2b |
protein tyrosine kinase 2 beta |
|
multiple interactions |
ISO |
15 |
45,589,222 |
45,717,866 |
RGD:6480464 |
CTD |
| G |
Ptk2b |
protein tyrosine kinase 2 beta |
|
increases phosphorylation |
ISO |
15 |
45,589,222 |
45,717,866 |
RGD:6480464 |
CTD |
| G |
Ralbp1 |
ralA binding protein 1 |
|
multiple interactions |
ISO |
9 |
104,617,400 |
104,653,856 |
RGD:6480464 |
CTD |
| G |
Ralbp1 |
ralA binding protein 1 |
|
affects transport |
ISO |
9 |
104,617,400 |
104,653,856 |
RGD:6480464 |
CTD |
| G |
Rassf1 |
Ras association (RalGDS/AF-6) domain family member 1 |
|
increases expression |
EXP |
8 |
112,798,863 |
112,810,004 |
RGD:6480464 |
CTD |
| G |
Rb1 |
retinoblastoma 1 |
|
multiple interactions |
ISO |
15 |
53,828,881 |
53,962,099 |
RGD:6480464 |
CTD |
| G |
S100a8 |
S100 calcium binding protein A8 |
|
increases expression |
EXP |
2 |
182,961,994 |
182,962,513 |
RGD:6480464 |
CTD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
increases expression |
EXP |
2 |
182,985,466 |
182,988,147 |
RGD:6480464 |
CTD |
| G |
Sct |
secretin |
|
multiple interactions |
EXP |
1 |
201,472,250 |
201,472,944 |
RGD:6480464 |
CTD |
| G |
Sele |
selectin E |
|
increases expression |
EXP |
13 |
79,813,455 |
79,822,845 |
RGD:6480464 |
CTD |
| G |
Serpina6 |
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 |
|
decreases transport |
EXP |
6 |
127,911,618 |
127,921,851 |
RGD:6480464 |
CTD |
| G |
Serpine1 |
serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 |
|
increases expression |
EXP |
12 |
20,931,996 |
20,942,374 |
RGD:6480464 |
CTD |
| G |
Sesn1 |
sestrin 1 |
|
increases expression |
EXP |
20 |
45,786,623 |
45,877,856 |
RGD:6480464 |
CTD |
| G |
Spon1 |
spondin 1, extracellular matrix protein |
|
increases expression |
EXP |
1 |
171,700,495 |
172,020,808 |
RGD:6480464 |
CTD |
| G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
|
multiple interactions |
ISO |
3 |
8,956,380 |
9,021,831 |
RGD:6480464 |
CTD |
| G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
|
increases cleavage |
ISO |
3 |
8,956,380 |
9,021,831 |
RGD:6480464 |
CTD |
| G |
Tat |
tyrosine aminotransferase |
|
multiple interactions |
ISO |
19 |
39,854,163 |
39,865,060 |
RGD:6480464 |
CTD |
| G |
Tat |
tyrosine aminotransferase |
|
decreases expression |
ISO |
19 |
39,854,163 |
39,865,060 |
RGD:6480464 |
CTD |
| G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
|
increases expression |
EXP |
4 |
28,807,080 |
28,811,502 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Tgfb1 |
transforming growth factor, beta 1 |
|
multiple interactions |
EXP |
1 |
80,894,705 |
80,911,020 |
RGD:6480464 |
CTD |
| G |
Thbd |
thrombomodulin |
|
increases expression |
EXP |
3 |
137,158,955 |
137,162,607 |
RGD:6480464 |
CTD |
| G |
Thbs1 |
thrombospondin 1 |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
|
increases expression |
EXP |
X |
12,542,496 |
12,547,094 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
decreases expression |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
multiple interactions |
EXP |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Tnfrsf1a |
tumor necrosis factor receptor superfamily, member 1a |
|
affects response to substance |
ISO |
4 |
162,172,563 |
162,185,252 |
RGD:6480464 |
CTD |
| G |
Tnni3 |
troponin I type 3 (cardiac) |
|
increases expression |
EXP |
1 |
68,028,198 |
68,031,882 |
RGD:6480464 |
CTD |
| G |
Tp53 |
tumor protein p53 |
|
multiple interactions |
ISO |
10 |
56,399,721 |
56,411,150 |
RGD:6480464 |
CTD |
| G |
Tpd52l1 |
tumor protein D52-like 1 |
|
increases expression |
EXP |
1 |
26,788,964 |
26,951,930 |
RGD:6480464 |
CTD |
| G |
Traf2 |
Tnf receptor-associated factor 2 |
|
affects response to substance |
ISO |
3 |
3,692,740 |
3,717,332 |
RGD:6480464 |
CTD |
| G |
Tuba1b |
tubulin, alpha 1B |
|
decreases expression |
EXP |
7 |
137,706,858 |
137,709,839 |
RGD:6480464 |
CTD |
| G |
Tuba4a |
tubulin, alpha 4A |
|
decreases expression |
EXP |
9 |
74,496,508 |
74,500,192 |
RGD:6480464 |
CTD |
| G |
Tubb4b |
tubulin, beta 4B class IVb |
|
decreases expression |
EXP |
3 |
3,387,050 |
3,389,500 |
RGD:6480464 |
CTD |
| G |
Tubb5 |
tubulin, beta 5 class I |
|
decreases expression |
EXP |
20 |
3,060,224 |
3,090,776 |
RGD:6480464 |
CTD |
| G |
Tubg1 |
tubulin, gamma 1 |
|
decreases expression |
EXP |
10 |
90,137,813 |
90,144,403 |
RGD:6480464 |
CTD |
| G |
Vcam1 |
vascular cell adhesion molecule 1 |
|
increases expression |
EXP |
2 |
212,277,654 |
212,297,376 |
RGD:6480464 |
CTD |
| G |
Vip |
vasoactive intestinal peptide |
|
increases expression |
EXP |
1 |
36,361,513 |
36,369,594 |
RGD:6480464 |
CTD |
| G |
Vip |
vasoactive intestinal peptide |
|
increases expression |
EXP |
1 |
36,361,513 |
36,369,594 |
RGD:6480464 |
CTD |
| G |
Vip |
vasoactive intestinal peptide |
|
increases expression |
EXP |
1 |
36,361,513 |
36,369,594 |
RGD:6480464 |
CTD |
Term paths to the root
|